BACKGROUND: The local-regional failure of advanced oral squamous cell carcinoma (OSCC) after surgery results from the regrowth of residual tumor cells that may be stimulated by epidermal growth factor receptor (EGFR) ligands during the wound healing process. METHODS: The level of EGFR ligands in human drain fluids (DFs) from OSCC resection and remote flap donor site were determined. A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth, survival, and cervical lymph node metastases. A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process. RESULTS: EGFR ligands are found in sites from OSCC resection. EGFR targeted therapy can delay tumor regrowth in a microscopic residual disease model of OSCC without significant effects on local wound healing. CONCLUSION: These results provide a strong rationale for clinical evaluation of this approach to treat patients with local-regionally advanced OSCC.
BACKGROUND: The local-regional failure of advanced oral squamous cell carcinoma (OSCC) after surgery results from the regrowth of residual tumor cells that may be stimulated by epidermal growth factor receptor (EGFR) ligands during the wound healing process. METHODS: The level of EGFR ligands in human drain fluids (DFs) from OSCC resection and remote flap donor site were determined. A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth, survival, and cervical lymph node metastases. A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process. RESULTS:EGFR ligands are found in sites from OSCC resection. EGFR targeted therapy can delay tumor regrowth in a microscopic residual disease model of OSCC without significant effects on local wound healing. CONCLUSION: These results provide a strong rationale for clinical evaluation of this approach to treat patients with local-regionally advanced OSCC.
Authors: Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: W Xia; Y K Lau; H Z Zhang; F Y Xiao; D A Johnston; A R Liu; L Li; R L Katz; M C Hung Journal: Clin Cancer Res Date: 1999-12 Impact factor: 12.531
Authors: Jeffrey N Myers; F Christopher Holsinger; Samar A Jasser; B Nebiyou Bekele; Isaiah J Fidler Journal: Clin Cancer Res Date: 2002-01 Impact factor: 12.531
Authors: N R Dean; L Sweeny; P M Harari; J A Bonner; V Jones; L Clemons; H Geye; E L Rosenthal Journal: J Wound Care Date: 2011-04 Impact factor: 2.072
Authors: K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang Journal: Int J Radiat Oncol Biol Phys Date: 2000-08-01 Impact factor: 7.038
Authors: C Hope Heath; Nicholas L Deep; Lisle Nabell; William R Carroll; Renee Desmond; Lisa Clemons; Sharon Spencer; J Scott Magnuson; Eben L Rosenthal Journal: Int J Radiat Oncol Biol Phys Date: 2012-11-22 Impact factor: 7.038